NCT06679296 Study on Aging and Cognitive Impairment in China
| NCT ID | NCT06679296 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Condition | Cognitive Dysfunction |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2033-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2024-11-20 with a primary completion date of 2033-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: By the end of 2022, China had about 280 million people aged 60 and older, making up 19.8% of the population. This number is projected to exceed 300 million by the end of the 14th Five-Year Plan and 400 million by 2035, which would be over 30%. The 20th National Congress emphasized the need for a proactive strategy to tackle aging challenges. Approximately 6.04% of the elderly have dementia, with 3.94% having Alzheimer's disease. This totals around 15 million people with dementia. To address this, the China Cohort Consortium on Aging and Cognitive Impairment Development has been proposed to study health and cognitive changes in different age groups, aiming to support healthy aging policies. Methods: Participants from various age groups (children, youth, middle-aged, elderly) will be recruited from hospitals, schools, and communities using stratified sampling. They will undergo detailed medical examinations focusing on aging, cognitive impairments, and related diseases. A new database will track healthy aging and cognitive impairment development. Content: The study will involve comprehensive medical examinations, including physiological assessments, psychological evaluations, cognitive screenings, daily life assessments, imaging studies, and blood tests, to establish a detailed health and cognitive impairment database. The research will also investigate integrated intervention models in hospital, community, and home settings, develop remote medical management systems, and devise biomarker test kits for aging and cognitive impairments. Furthermore, it will concentrate on non-pharmacological interventions and artificial intelligence systems for the early detection, prevention, and treatment of aging-related conditions. Objectives: The China Cohort Consortium on Aging and Cognitive Impairment Development, commencing with the HAPCAD study, aims to monitor changes across various age groups, evaluate the impact of aging on health and cognitive function, and design targeted interventions. The objective is to enhance health management and services related to aging, establish effective strategies, develop therapeutic drugs, and promote healthy aging.
Eligibility Criteria
Inclusion Criteria: 1. Ability to sign an informed consent form: Participants and/or their legally authorized representatives, in case of diminished decision-making capacity, are capable of reading, understanding, and providing written informed consent as per national legal requirements. 2. Capability to complete assessments independently or with assistance. 3. Willingness and ability to fulfill all study requirements, including peripheral organ function assessments, EEG, lumbar puncture, MRI, and PET imaging examinations. 4. Agreement to participate in follow-up visits. Exclusion Criteria: 1. Terminal stage of significant diseases such as malignant tumors or autoimmune diseases at enrollment; 2. Substance abusers.
Contact & Investigator
Weihong Song Prof.
STUDY CHAIR
First Affiliated Hospital of Wenzhou Medical University
Frequently Asked Questions
Who can join the NCT06679296 clinical trial?
This trial is open to participants of all sexes, studying Cognitive Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06679296 currently recruiting?
Yes, NCT06679296 is actively recruiting participants. Contact the research team at pansipei@wmu.edu.cn for enrollment information.
Where is the NCT06679296 trial being conducted?
This trial is being conducted at Wenzhou, China.
Who is sponsoring the NCT06679296 clinical trial?
NCT06679296 is sponsored by First Affiliated Hospital of Wenzhou Medical University. The principal investigator is Weihong Song Prof. at First Affiliated Hospital of Wenzhou Medical University. The trial plans to enroll 20,000 participants.